- Impact of BOLERO-2 study results on clinical practice and future treatment of postmenopausal patients with advance HR+/HER2- breast cancer2014 | First Faculty of Medicine
- Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer2020 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Lapatinib in second line treatment of metastatic HER2+ breast cancer2012 | First Faculty of Medicine
- Use of Trastuzumab for Neoadjuvant Therapy of HER2+ Breast Cancer - 5-Years of Experience in a Single Clinic2018 | First Faculty of Medicine
- The optimal treatment of patients with HER2+ breast cancer and metastatic spread to the brain2012 | First Faculty of Medicine
- New agent to enhance targeted therapy of metastatic HER2+ breast cancer - pertuzumab2013 | First Faculty of Medicine
- Palbociclib as one of the CDK4/6 inhibitors is of undisputed importance to women with advanced HR+/HER2- breast cancer2019 | Faculty of Medicine in Pilsen
- Using 'Costs States' in a Semi-Markov Model to Estimate Cost-Effectiveness with an Illustration for Metastatic HER2 Breast Cancer in the Czech RepublicPublication without faculty affiliation
- Research Report University Hospital for clinical assessment A5481008Publication without faculty affiliation
- The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States2023 | Faculty of Social Sciences
- FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer2009 | Third Faculty of Medicine
- Using 'Costs States' in a Semi-Markov Model to Estimate Cost-Effectiveness: an Illustration for Metastatic HER2 Breast Cancer in the Czech Republic2020 | Faculty of Social Sciences
- Targeted biological treatment of solid tumors. Controversy treatment HER2 dependent breast cancer2009 | First Faculty of Medicine
- Lapatinib in generalized breast cancer2009 | First Faculty of Medicine
- Biological treatment with trastuzumab in the neoadjuvant therapy of breast cancer2009 | First Faculty of Medicine
- News in anti-HER2 targeted therapy in breast cancer +12013 | First Faculty of Medicine
- Effect of neoadjuvant Herceptin (trastuzumab) in a patient with breast cancer with high growth activity2009 | First Faculty of Medicine
- The advantage of Herceptin SC and advantage of the originator2017 | Faculty of Medicine in Pilsen
- First experience with Oncotype DX test in patients with breast cancer2015 | First Faculty of Medicine
- Genomic tests as predictors of breast cancer patients' prognosis2016 | First Faculty of Medicine
- AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers2023 | First Faculty of Medicine
